Injectable DMT Formulation Using Cyclodextrin Complexation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable, ready-to-use N,N-Dimethyltryptamine formulation that minimizes degradation and maintains effectiveness over prolonged storage periods under predefined conditions.
Innovation Solution
A formulation comprising N,N-Dimethyltryptamine with specific concentrations of buffer, cyclodextrin, solubilizer, and tonicity agent, adjusted to a pH range of 3-6, which results in an osmolarity of 250-600 mOsm/kg, ensuring stability under refrigerated and controlled room temperature conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If N,N-Dimethyltryptamine is formulated as a liquid preparation, then ease of administration and therapeutic effectiveness are improved, but stability and degradation over time worsen
Solution Approach 1:
Cyclodextrins are used as intermediary molecules that form inclusion complexes with N,N-Dimethyltryptamine. The cyclodextrin cavity encapsulates the active ingredient, protecting it from degradation while maintaining solubility and ease of administration in liquid form.
Solution Approach 2:
The formulation optimizes multiple parameters including pH (adjusted to acidic range using buffers like citrate or acetate), temperature (refrigerated storage), and composition ratios to maximize stability. These parameter changes transform the unstable liquid into a stable therapeutic preparation.
2Reliability
If the formulation uses higher concentrations of active ingredient, then therapeutic effectiveness is improved, but stability and degradation resistance worsen
Solution Approach 1:
The formulation creates a composite system where N,N-Dimethyltryptamine is combined with cyclodextrins, buffers, and other excipients. This composite structure allows higher concentrations of the active ingredient to be stabilized through the protective cyclodextrin inclusion complexes and buffered environment.
3Productivity
If the formulation is prepared as ready-to-use liquid, then productivity and ease of use are improved, but storage stability and shelf life worsen
Solution Approach 1:
The formulation is prepared in advance with all stabilizing components (cyclodextrins, buffers, preservatives) already in place to prevent degradation. This preliminary stabilization action enables the liquid formulation to maintain stability throughout its shelf life while remaining ready for immediate use.
Solution Approach 2:
The formulation creates a chemically inert environment through buffering systems and antioxidant components that prevent oxidative degradation and other chemical reactions, effectively creating a protective atmosphere within the liquid preparation that extends shelf life.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation minimizes degradation products and maintains stability for at least 14 days to 12 months, retaining active ingredient and clarity without visible particles, suitable for various psychological and physiological therapeutic uses.
Implementation Method 1
a cyclodextrin component in the range of 5-15 mM
Implementation Method 2
a buffer component with acidic acid in the range of 2-15 mM
Data Source
AI summary
Aspects of the invention can include a composition including an N,N-Dimethyltryptamine base in the range of 0.5-5 mg/mL, a buffer component with acidic acid in the range of 2-15 mM, a cyclodextrin component in the range of 5-15 mM, and a solubilizer component in the range of 1-5 mM; The composition can also include a tonicity agent, wherein the tonicity agent causes an osmolarity of the composition to be in the range of 250-600 mOsm/kg, wherein the composition has a pH in the range of 3-6.